Literature DB >> 18670066

Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.

Mikołaj Łaniewski-Wołłk1, Monika Gos, Andrzej Koziarski, Agnieszka Szpecht-Potocka.   

Abstract

Point mutation and loss of heterozygosity (LOH) analyses were performed in 12 Polish patients with a classic symptom of NF2 - bilateral vestibular schwannomas (BVS). In 5 patients (41.7%), germline mutations were found in the NF2 gene: 2 previously reported substitutions (c.592C>T and c.52C>T) and 3 novel mutations (c.1001_1002insG, c.1029_1030insCC, c.774_778dupGAATG). In addition, LOH analysis of 30 tumour samples from 10 patients revealed a molecular basis of NF2 in 3 patients (25%) that did not have any germline mutation. The molecular defects in sporadic cases of NF2 are still being discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18670066     DOI: 10.1007/BF03195626

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  21 in total

1.  Schwannomin isoform-1 interacts with syntenin via PDZ domains.

Authors:  M Jannatipour; P Dion; S Khan; H Jindal; X Fan; J Laganière; A H Chishti; G A Rouleau
Journal:  J Biol Chem       Date:  2001-06-29       Impact factor: 5.157

2.  The neuroimaging and clinical spectrum of neurofibromatosis 2.

Authors:  V F Mautner; M Lindenau; M E Baser; W Hazim; M Tatagiba; W Haase; M Samii; R Wais; S M Pulst
Journal:  Neurosurgery       Date:  1996-05       Impact factor: 4.654

3.  Evaluation of clinical diagnostic criteria for neurofibromatosis 2.

Authors:  M E Baser; J M Friedman; A J Wallace; R T Ramsden; H Joe; D G R Evans
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

4.  Merlin: hanging tumor suppression on the Rac.

Authors:  L S Sherman; D H Gutmann
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

5.  Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease.

Authors:  M H Ruttledge; A A Andermann; C M Phelan; J O Claudio; F Y Han; N Chretien; S Rangaratnam; M MacCollin; P Short; D Parry; V Michels; V M Riccardi; R Weksberg; K Kitamura; J M Bradburn; B D Hall; P Propping; G A Rouleau
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

6.  Interdomain binding mediates tumor growth suppression by the NF2 gene product.

Authors:  L Sherman; H M Xu; R T Geist; S Saporito-Irwin; N Howells; H Ponta; P Herrlich; D H Gutmann
Journal:  Oncogene       Date:  1997-11-13       Impact factor: 9.867

7.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

8.  Exon scanning for mutation of the NF2 gene in schwannomas.

Authors:  L B Jacoby; M MacCollin; D N Louis; T Mohney; M P Rubio; K Pulaski; J A Trofatter; N Kley; B Seizinger; V Ramesh
Journal:  Hum Mol Genet       Date:  1994-03       Impact factor: 6.150

9.  Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.

Authors:  L Kluwe; V Mautner; B Heinrich; R Dezube; L B Jacoby; R E Friedrich; M MacCollin
Journal:  J Med Genet       Date:  2003-02       Impact factor: 6.318

10.  Normal membrane localization and actin association of the NF2 tumor suppressor protein are dependent on folding of its N-terminal domain.

Authors:  E Brault; A Gautreau; M Lamarine; I Callebaut; G Thomas; L Goutebroze
Journal:  J Cell Sci       Date:  2001-05       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.